Company: LENZ
Filing Date: 2025-10-08
Form Type: 8-K
Source: 0001815776-25-000064
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-10-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On October 7, 2025, the Company sold 1,748,634 shares of common stock at a purchase price of $45.75 per share for gross proceeds of approximately $80,000,000 in a block trade to a single investor under the Company's "at the market" Sales Agreement with TD Securities (USA) LLC, dated as of April 4, 2025 (the "Sales Agreement"). The sale was made pursuant and subject to the terms of the Sales Agreement, a copy of which was filed with the Current Report on Form 8-K filed by the Company on April 4, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 8, 2025

  LENZ THERAPEUTICS, INC.                                                    
  By:                          /s/ Daniel Chevallard                         
  Name:                        Daniel Chevallard                             
  Title:                       Chief Financial Officer                       
                               (Principal Financial and Accounting Officer)